Spectrum Equity has invested in Agilis Systems. Financial terms weren’t announced. Agilis, of Chesterfield, Missouri, provides tracking systems that help businesses manage their mobile fleets and ...

Very effective venting at all speeds, MIPS protection and increased coverage make the Giro Agilis helmet a great all-road choice You can trust Cyclingnews Our experts spend countless hours testing ...

BOSTON, Dec. 12, 2024 /PRNewswire/ -- Agilis Partners LLC, a leading investment, actuarial and risk management group, is proud to announce two major achievements: winning the CIO Industry Innovation ...

BOSTON, Sept. 3, 2024 /PRNewswire/ -- Agilis Partners LLC, a leading investment, actuarial and risk management group, is proud to announce that James Walton, Managing Director at Agilis, has been ...

Michelin is expanding its Agilis HD family of tires. The tire lineup is engineered for superior longevity, class-leading durability and optimum traction, according to the OE. Michelin said the new ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Since 2002, Gallagher has made ...

Qualitative jet tender should not only perform its main function – transfer guests and owners from shore to yachts, but also be customized in accordance with all requirements and taste preferences of ...

Rotor follows a different path with its new Ágilis XC2 mountain bike crankset but the result is a capable performer nonetheless. Rather than the currently popular carbon fibre or hollow-forged ...

CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)--Agilis Biotherapeutics, Inc. (Agilis), a biotechnology company advancing innovative DNA therapeutics for rare genetic diseases that affect the central ...

Agilis Biotherapeutics has formed a joint venture with Japan’s Gene Therapy Research Institution (GTRI). The alliance gives Agilis a base in Japan and a partnership with a fellow CNS specialist to ...

, a synthetic biology-based company focused on developing DNA-based therapeutics for rare genetic diseases, announced today that George S. Zorich has been named Chief Executive Officer of the company.